PSMA ADC is a fully human monoclonal antibody-drug conjugate designed to deliver chemotherapeutic drug to prostate cancer cells by targeting PSMA, a protein that is a biomarker of prostate cancer. The PSMA antibody is designed enter the cancer cell and release active anti-cancer drug.
“Our extensive commercial manufacturing experience and proven quality systems make Gallus an ideal partner to support Progenics in the manufacture of their anti-PSMA antibody," said Mark R. Bamforth, president and chief executive officer of Gallus. "We look forward to working with Progenics as they advance this treatment for patients with prostate cancer."
"Gallus has impressed us with their ability to meet our high standards, combined with the experience and expertise necessary to manufacture our anti-PSMA antibody,” said Nitya Ray, Ph.D., senior vice president of manufacturing at Progenics. “We look forward to a productive partnership with Gallus as we develop this product for patients in need of this therapy."